The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of definitive radiotherapy with leuprolide and enzalutamide in high-risk prostate cancer.
 
Claire Marie de la Calle
No Relationships to Disclose
 
Albert Chang
No Relationships to Disclose
 
Ghezal Rashid
No Relationships to Disclose
 
Anthony C. Wong
No Relationships to Disclose
 
Alice Choi
No Relationships to Disclose
 
Felix Y Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - Nutcracker Therapeutics, Inc.; PFS Genomics; SerImmune
Honoraria - Genentech
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Celgene; EMD Serono; Genzyme; Janssen Biotech; Medivation/Astellas
Research Funding - Zenith Epigenetics
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)
 
Alexander R. Gottschalk
No Relationships to Disclose
 
Paul Lawrence Menzel
No Relationships to Disclose
 
Peter Carroll
Honoraria - Intuitive Surgical
Consulting or Advisory Role - Nutcracker Therapeutics, Inc.
 
Hao Gia Nguyen
No Relationships to Disclose